WO2001048227A1 - Method for production of proteins in host cells involving the use of chaperonins - Google Patents
Method for production of proteins in host cells involving the use of chaperonins Download PDFInfo
- Publication number
- WO2001048227A1 WO2001048227A1 PCT/US2000/034055 US0034055W WO0148227A1 WO 2001048227 A1 WO2001048227 A1 WO 2001048227A1 US 0034055 W US0034055 W US 0034055W WO 0148227 A1 WO0148227 A1 WO 0148227A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chaperonin
- protein
- binding domain
- host cell
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Definitions
- the present invention generally relates to methods for the production of proteins in host cells. Specifically, the present invention relates to the use of a chaperonin binding domain in expression systems designed for the production of proteins in host cells.
- the large scale production of a protein is limited by the toxicity of the overexpressed protein toward the host cell or the accumulation of proteins as inclusion bodies that impede their recovery and purification.
- a class of accessory proteins known as molecular chaperones function by interacting with nascent polypeptide chains and aid in the process of correct folding Georgiou et al. (1996, Current Opinion in Biotechnology, 7:190-197).
- Molecular chaperones are highly conserved proteins found in all organisms that control and sometimes catalyse the ATP- dependent folding of newly synthesized proteins and polypeptides as they are produced in cells.
- Chaperones mediate the stabilization and refolding of proteins under conditions of stress and are believed to fold crucial portions of proteins, such as enzymes, independently (Hendrick, J.P., 1993, Ann. Rev. Biochem. 62: 349-384).
- Hsp60 heat shock protein
- GroEL a chaperonin and the smaller accessory protein GroES (10kDa); the DnaK (Hsp70), DnaJ and GrpE complex; and the Clp system.
- GroEL consists of 14 subunits which are arranged in two heptameric rings stacked back to back. The central cavity of the cylinder accepts unfolded substrate polypeptides in the conformation of a collapsed intermediate. GroEL interacts with GroES, a single heptameric ring that binds asymetrically to GroEL, capping one opening of the cylinder.
- GroES coordinates the ATP hydrolysis by GroEL with productive folding (Mayhew, M et al., Nature vol. 379:420-426.) Dale, G. et al. (1994, Protein Engineering 7:925-931 ) report that simultaneous overproduction of the GroEL/GroES chaperonins with dihydrofolate reductase results in an increased solubility of the enzyme and Amrein, K. et al. (1995, Proc. Natl. Acad. Sci. vol 92: 1048-1052) report on the purification of recombinant human protein-tyrosine kinase in an E.coli expression system overproducing the bacterial chaperonins GroES and GroEL.
- the present invention generally relates to chaperonin protein binding domains and to the use of an isolated chaperonin protein binding domain in the production of heterologous proteins, peptides or polypeptides in a host cell.
- the present invention is based, in part, upon the finding that a toxic gene product could be recombinantly produced by a host cell when expressed as a fusion protein associated with an isolated chaperonin binding domain.
- the present invention provides a method for producing a protein in a host cell, comprising the step of culturing a host cell comprising a first nucleic acid encoding an isolated chaperonin binding domain associated with a second nucleic acid encoding the protein and a third nucleic acid encoding a chaperonin under conditions suitable for expression of said first, said second and said third nucleic acid and wherein said chaperonin binding domain is capable of binding to said chaperonin.
- the chaperonin binding domain and the chaperonin are capable of binding with an affinity of between about 10 "2 and 10 "8 Kd.
- the method may further comprise recovering said protein from said cell.
- the protein is one toxic to the host cell.
- a protein may be toxic to a host cell due to its intrinsic nature or toxic due to the presence of elevated levels in the host cell.
- the first and second nucleic acid encode a fusion protein.
- the first and second nucleic acid may be directly linked or indirectly linked by nucleic acid encoding an enzymatic cleavage site, a chemical cleavage site, or another protein or peptide.
- nucleic acid encoding the chaperonin is naturally produced by the host cell and the cell is grown under conditions that result in elevated levels of the chaperonin.
- nucleic acid encoding the chaperonin is heterologous to the host cell and the heterologous chaperonin is under the control of at least one expression signal capable of overexpressing the chaperonin in the host cell.
- the present invention encompasses any host cell that is capable of expression of recombinant proteins.
- the host cell is a bacterium.
- the host cell is a eubacterium.
- the host cell is a gram-positive or a gram-negative bacterium.
- the bacterial cell is a member of the family Enterobacteriaceae..
- the bacterial cell is an Escherichia species, in particular E. coli.
- chaperonin binding domains obtainable from these systems as long as the chaperonin binding domain is capable of binding to a chaperonin with an affinity of between about 10 ⁇ 2 and 10 "8 Kd.
- the chaperonin binding domain has the sequence as shown in SEQ ID NO: 1 through SEQ ID NO: 38.
- the chaperonin binding domain is obtainable from the GroES co-chaperonin and said chaperonin is the GroEL chaperonin.
- the binding domain comprises the amino acid sequence EVETKSAGGIVLTGSAAA.
- the binding domain comprises a variation of the sequence EVETKSAGGIVLTGSAAA, said variant being capable of binding to GroEL chaperonin with an affinity of 10 "2 to 10 "8 Kd.
- the present invention also provides expression vectors and host cells comprising a chaperonin protein binding domain.
- heterologous proteins include therapeutically significant proteins, such as growth factors, cytokines, ligands, receptors and inhibitors, as well as vaccines and antibodies; enzymes such as hydrolases including proteases, carbohydrases, and lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases and phophatases; and commercially important industrial proteins or polypeptides, such as proteases, carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases.
- the nucleic acid encoding the heterologous protein may be naturally occurring, a variation of a naturally occurring protein or synthetic.
- Figure 1 shows the nucleic acid (SEQ ID NO:1 ) and amino acid (SEQ ID NO:2) for the region of the chaperonin containing the GroEL/GroES binding domain.
- Figure 2 shows the growth of JM105 in the presence of increasing amount of ethanol:
- Figure 3 shows the growth rate of BAX transformants with different leader sequences in the presence and absence of 2% ethanol.
- Figure 4 shows and analysis of proteins present upon induction of the host cells with IPTG and growth in the presence of ethanol.
- Figure 5 shows the design of a linker for attaching the GroEL-binding loop of GroES to proteins. Oligonucleotides matching the two sequences shown above were synthesized chemically, annealed to generate the duplex DNA fragment, and cloned into appropriate vectors. Linkage to a gene via the EcoRI overhang generates protein 20 amino acids (1905 Daltons) longer.
- chaperonin refers to those molecules including heat shock proteins Hsp60 and like proteins that are expressed in any organism which are associated with protein folding.
- the present invention encompasses any chaperonin from any microbial source, virus or bacteriophage including the chaperonin systems, Hsp60 and Hsp10
- the chaperonin binding domain and the chaperonin are obtainable from the heat shock protein 60 (HSP60) class of proteins.
- chaperonins include mammalian or yeast HSP68, HSP70, HSP72, HSP73, clathrin uncoating ATPase, IpG heavy chain binding protein (BiP), glucose-regulated proteins 75, 78, and 80 (GRP75, GRP78, and GRP80), HSC70, and yeast KAR2, BiP, SSA1-4, SSB1 , SSD1 and the like.
- Chaperone proteins which can increase protein secretion also include enzymes which catalyze covalent modification of proteins, such as mammalian or yeast protein disulfide isomerase (PDI), prolyl-4-hydroxylase B-subunit, ER p59, glycosylation site binding protein (GSBP) and thyroid hormone binding protein (T3BP).
- PDI mammalian or yeast protein disulfide isomerase
- prolyl-4-hydroxylase B-subunit prolyl-4-hydroxylase B-subunit
- ER p59 glycosylation site binding protein
- T3BP thyroid hormone binding protein
- Chaperonins are known to be associated with protein folding and anti-aggregation activities (Craig, et al., 1994, Cell vol. 78, 365-372; Hendrick, et al., 1993, Annu. Rev. Biochem. Vol. 62, 349-84; Hartl, 1994, TIBS vol.19:20-25). Often, multiple sub-units are associated with one chaperonin complex.
- the present invention encompasses each chaperonin sub-unit used individually or in combination with other subunits providing that the individual subunit or combination of subunits is able to function by binding to a chaperonin protein binding domain.
- preferred chaperonins are those present in members of the family Enterobacteriaceae and in particular from Eschericia species.
- a preferred chaperonin is the GroEL chaperonin which is associated with the co-chaperonin GroES.
- a chaperonin of the present invention may be naturally occurring in the host cell or heterologous to the host cell and may be introduced by recombinant means.
- the phrase "isolated binding domain" of a chaperonin or “chaperonin protein binding domain” or “chaperonin binding domain” refers to a region of a protein or polypeptide that is able to bind with an affinity of between 10 "2 and 10 ⁇ 8 Kd to a chaperonin or portion or fragment thereof of said chaperonin.
- the chaperonin binding domain has the sequence as shown in any of SEQ ID NO: 1 through SEQ ID NO:38.
- the chaperonin binding domain is obtainable from the GroES co-chaperonin.
- the chaperonin protein binding domain obtainable from GroES refers to the residues shown in Figure 1 comprising the sequence EVETKSAGGIVLTGSAAA.
- the binding domain comprises amino acid variations of EVETKSAGGIVLTGSAAA capable of binding to a GroEL chaperonin with an affinity of between 10 "2 and 10 "8 Kd.
- a chaperonin protein binding domain is associated with a second nucleic acid encoding a heterologous protein when the first and second nucleic acids are directed linked, such as in a fusion protein, or are indirectly linked such as having an enzymatic cleavage site, chemical cleavage site or other nucleic acid inserted between the first and the second nucleic acid.
- nucleic acid refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be double-stranded or single-stranded, whether representing the sense or antisense strand.
- amino acid refers to peptide or protein sequences or portions thereof.
- isolated or purified refer to a nucleic acid or amino acid that is removed from at least one component with which it is naturally associated.
- heterologous protein refers to a protein or polypeptide that is encoded by nucleic acid introduced into a host cell.
- heterologous proteins include enzymes such as hydrolases including proteases, carbohydrases, and lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases and phophatases.
- the heterologous gene may encode therapeutically significant proteins or peptides, such as growth factors, cytokines, ligands, receptors and inhibitors, as well as vaccines and antibodies.
- the gene may encode commercially important industrial proteins or peptides, such as proteases, carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases.
- the gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene.
- the term "homologous protein” refers to a protein or polypeptide that naturally occurs in the host cell.
- the present invention encompasses homologous proteins that are introduced into the host cell via recombinant means.
- the term "toxic” as used herein refers to any protein that inhibits the growth of a bacterial cell.
- a protein may be toxic to a host cell due to an intrinsic harmful nature or due to expression levels in the host bacterial cell.
- An illustrative example of a toxic protein disclosed herein is the mouse apoptosis modulator protein, Bax. Examples of proteins considered to be toxic due to their intrinsic nature include nucleoses, proteoses and phospholipo
- the term "overexpressing" when referring to the production of a protein in a host cell means that the protein is produced in greater amounts than it is produced in its naturally occurring environment.
- the present invention provides a means for the production of proteins or polypeptides in a host cell, especially proteins or polypeptides that are toxic to the cell due to the protein's intrinsic nature or due to expression levels of the protein produced recombinantly in the cell.
- the present invention provides methods for producing a protein in a host cell wherein the cell comprises nucleic acid encoding a fusion protein comprising a chaperonin binding domain and the protein and wherein the cell naturally produces a chaperonin that binds to the chaperonin binding domain.
- the host cell is grown under conditions suitable for inducing or enhancing the levels of the naturally occurring chaperonin.
- the present invention encompasses methods for producing a protein in a host cell wherein the cell comprises nucleic acid encoding a fusion protein comprising a chaperonin binding domain and protein and said host cell further comprises nucleic acid encoding a chaperonin that has been recombinantly introduced into said host cell.
- the chaperonin may be homologous or heterologous to said host cell and is associated with expression signals capable of overexpressing the chaperonin.
- the mammalian gene bax a member of the bcl-2 family of apoptosis modulators (Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. (1993) Bcl-2 Heterodimerizes in vivo with a conserved Homolog, Bax, that accelerates Programmed cell death, Cell 74, 609-619) was used.
- bax Although homologous to bcl-2 and bcl- X L , which inhibit apoptosis, bax has the opposite function and is an effector of cell death (McDonnell, T.J., et al., 1996, Importance of the Bcl-2 family in cell death regulation, Experientia 52, 1008-1017). These three genes were expressed in E. coli as fusions with the OmpA leader sequence. Bcl-2 and Bcl-X proteins were produced in the periplasm of E. coli, but only trace amounts of Bax was produced by this approach. Expression of Bax appeared to be highly toxic to the host cell.
- the present invention encompasses chaperonin proteins that are associated with increased protein secretion and those that are associated with the folding and unfolding of polypeptides, including but not limited to, the heat shock 60 family of proteins (Hsp60).
- the chaperonin is obtained from an organism listed in Table I and has the respective chaperonin binding domain as given in Table I.
- the chaperonin is GroEL the nucleic acid and amino acid sequence of which is disclosed in Hemmingsen, et al., 1988, Nature vol. 333, pages 330-334 . A method for isolation of GroEL is described, for example, in the reference Hendrix, R.W. 1979, J. Mol. Biol. 129:375-392.
- the chaperonin may be naturally occurring in the host cell in which case the host cell comprising the chaperonin is subjected to conditions that result in an increase in the production of the chaperonin. This provides elevated levels of chaperonin to which the chaperonin binding domain attaches.
- Methods for inducing the natural levels of chaperonin in a host cell include heat shock (Welch W.J., 1993, Philos Trans R. soc Lond B Biol Sci vol. 339, pages 327-333); chemical shock, such as by the addition of ethanol, methanol, glucose, and drugs such as those described in Volker et al., 1994, Microbiology, vol 140: pages 741- 752; Barbosa et al., Gene, 1994, vol.
- the chaperonin may be heterologous to the cell and introduced into the cell via recombinant means.
- the heterologous chaperonin, or portions or fragments thereof capable of binding to the chaperonin binding domain may be introduced via a replicating plasmid or integrated into the host genome by means known to those of skill in the art.
- the present invention also encompasses host cells having additional copies of homologous chaperonins, or portions or fragments thereof capable of binding to a chaperonin binding domain, introduced into the cell.
- the host cell used was E.coli which naturally produced the GroEL chaperonin as well as the GroES co-chaperonin, and further comprised nucleic acid encoding a fusion of the chaperonin binding domain having the amino acid sequence EVETKSAGGIVLTGSAAA with the mouse apoptosis modulator protein, Bax.
- the recombinant E.coli was subjected to growth conditions that stimulated overproduction of the naturally occurring GroEL chaperonin and expression of the fusion protein was observed. II. Chaperonin binding domain
- the present invention encompasses chaperonin binding domains that are capable of binding to a chaperonin with an affinity of between 10 '2 andlO "8 Kd.
- Examples of chaperonin binding domains are provided in Table I. Table I provides the sequence of chaperonin binding domains and a list of the respective microorganism from which the binding domain is obtained (Hunt et al., 1996, Nature vol. 379, pages 37-45).
- the chaperonin binding domain is the sequence EVETKSAGGIVLTGSAAA or portions or variations thereof which bind to the GroEL chaperonin with an affinity of between about 10 "2 to about 10 "8 Kd.
- the chaperonin binding domain may be directly linked to the desired protein, peptide or polypeptide, or indirectly linked, ie comprising additional nucleic acid between the nucleic acid encoding the chaperonin binding domain and the protein or peptide or polypeptide.
- additional nucleic acid may encode enzymatic cleavage sites or chemical cleavage sites.
- Nucleic acid encoding the chaperonin may be 5' or 3' to the nucleic acid encoding the protein, peptide or polypeptide.
- the present invention encompasses expression vectors and host cells comprising a chaperonin binding domain for the production of proteins, peptides or polypeptides in host cells.
- Nucleic acid encoding a chaperonin binding domain can be isolated from a naturally occurring source or chemically synthesized as can nucleic acid encoding a desired protein, peptide or polypeptide. Once nucleic acid encoding a binding domain of the present invention, or a protein, peptide or polypeptide, is obtained, fusion proteins comprising the chaperonin binding domain and the protein, peptide or polypeptide and recombinant host cells comprising the fusion proteins may be constructed using techniques well known in the art. Molecular biology techniques are disclosed in Sambrook et al., Molecular Biology
- nucleic acid encoding a chaperonin binding domain and/or protein is obtained and transformed into a host cell using appropriate vectors.
- vectors and transformation and expression cassettes suitable for the cloning, transformation and expression in host cells are known by those of skill in the art.
- the vector or cassette contains sequences directing transcription and translation of the nucleic acid, a selectable marker, and sequences allowing autonomous replication or chromosomal integration.
- Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. These control regions may be derived from genes homologous or heterologous to the host as long as the control region selected is able to function in the host cell.
- Initiation control regions or promoters which are useful to drive expression of the chaperonin binding domain, or fusion protein comprising the chaperonin binding domain, in a host cell are known to those skilled in the art. Virtually any promoter capable of driving expression is suitable for the present invention. Nucleic acid encoding the chaperonin binding domain is linked operably through initiation codons to selected expression control regions for effective expression of the chaperonin binding domain.
- a host cell which contains the coding sequence for a chaperonin or chaperonin binding domain of the present invention and expresses the protein may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane-based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.
- a host cell comprising a fusion protein comprising a chaperonin binding domain is used to express proteins, peptides or polypeptides which are normally toxic to the host cell,
- a toxic protein may affect the growth of the cell due to its intrinsic qualities or due to the affects on the cell due to overexpression.
- E. coli strain JM83 was obtained from Dr. Deborah Hanson, Argonne National
- PCR polymerase chain reactions
- Plamsid Components Source and/or reference pASK40 bla, laclq, P/Olac, t Ipp, f1-IG, ompA (Skerra et al., supra)
- Vectors designed to comprise the chaperonin binding domain obtainable from GroES were constructed as follows. Oligonucleotides were synthesized based on the published amino acid sequence of the E. coli GroES protein. Residues 16 through 33 comprise the chaperonin binding domain EVETKSAGGIVLTGSAAA. A nucleotide sequence encoding this sequence and its complement were generated by the program Lasergene (DNAStar, Inc., Madison, Wl.) using the general codon preferences for E. coli. A linker was designed to require the same reading frame as that required in pASK40. Additional nucleotides encoding the overhang generated by an EcoRI digest of DNA and an ATG initiation codon were included at the 5'-end of each to give:
- Oligo ATP6 5'-AATTATGGAAGTTGAAACCAAATGTGCTGGTGGTATCG- -TTCTGACCGGTTCTGCTGCTGCG-3'
- Oligo ATP7 5'-AATTCGCAGCAGCAGAACCGGTCAGAACGATACCACCA-
- the design of the linker for attachment of the GroEL-binding domain of GroES to proteins is shown in Figure 5.
- the linker was phosphorylated using T4 polynucleotide kinase, purified with Qiaex resin (Qiagen), and ligated into the dephosphorylated EcoRI site of the vector pJF118EH.
- Transductants of strain JM105 were screened for the presence of an EcoRI site, which is present in the linker but absent in pJF118EH. Positive transductants were screened for orientation of the insert. Only one end regenerates an EcoRI site, and in the correct orientation that site is adjacent to a multicloning site.
- EcoRI-EcoRV digests were analyzed on a 1.5% agarose gel for the presence of the 1 ,260 base pair fragment predicted for the correct orientation as opposed to the 1 ,200 base pair fragment predicted for the reverse orientation.
- the new vector was designated pATP004.
- Cell pellets (7.85 OD600 units) were lysed in 1 mL of a solution containing 9 M urea, 2% 2-mercaptoethanol, 4% Nonidet P40, and 2% ampholytes (BioRad pH 8-10). The resulting homogenates were centrifuged for 5 min at 435 x g in a Beckman TL100 tabletop ultracentrifuge to remove particulates. The supernatants were then frozen at -70° C until electrophoresis. Isoelectric focusing in the first dimension was done essentially as described by Anderson and Anderson (1978, Anal. Biochem, vol.
- a synthetic linker designed to encode the chaperonin binding loop of GroES (EVETKSAGGIVLTGSAAA) was ligated into the EcoRI site of plasmid pJF118EH. Plasmid DNA was prepared from representative colonies arising from transformation of E. coli JM105 with this ligation mixture, and screened for the presence of an Agel site, which is unique to the introduced linker. Of 10 colonies screened, all contained the site. The plasmids were then screened for orientation of the linker, since it could be incorporated in two directions. The linker was designed so that only one EcoRI site would be regenerated, which in the desired orientation would be attached to the multi-cloning site.
- Plasmids were digested with EcoRI and EcoRV (present in the tac promoter) and analyzed on a 1.5% gel.
- the desired orientation present in 5 of the plasmids, generated a 1 ,260 base-pair fragment; those in the wrong orientation, with the reconstituted EcoRI site at the downstream side of the inserted linker, generated a fragment of 1 ,200 basepairs.
- a representative of the correct orientation was propagated and designated pATP004.
- the small multi-cloning site of pAF1 18EH was excised from pATP004 by digesting it with EcoRI and Hindlll, and replaced with the EcoRI- Hindlll multi-cloning site of pUC19. Of eight colonies screened, seven contained the inserted multi-cloning site. These were further shown to have the expected orientation and the additional restriction sites. A representative colony was designated pATPOO ⁇ .
- the vectors described above initiate protein synthesis at the ATG codon in the new linker sequence that encodes EVETKSAGGIVLTGSAAA.
- the vector's multi-cloning site follows this linker, and genes are introduced into the cloning sites such that their reading frame matches that of the linker.
- the gene encoding mouse Bax was cloned from the pSK-mBax vector and the gene encoding murine Bcl-2 was cloned from cDNA by PCR as described in Materials and Methods.
- the bax gene was subsequently moved into the EcoRI-BamH1 sites of pATP004 to give the vector pATPO11. Genes encoding the BAX homolog Bcl-2 and the E. coli MDH were also recloned into pATP004 by standard methods.
- Example III Example III
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002385766A CA2385766C (en) | 1999-12-23 | 2000-12-14 | Methods for production of proteins in host cells |
DE60011785T DE60011785T2 (en) | 1999-12-23 | 2000-12-14 | PROCESS FOR THE PREPARATION OF PROTEINS IN HOST CELLS USING CHAPERONINES |
EP00988086A EP1208213B1 (en) | 1999-12-23 | 2000-12-14 | Method for production of proteins in host cells involving the use of chaperonins |
AU24334/01A AU2433401A (en) | 1999-12-23 | 2000-12-14 | Methods for production of proteins in host cells |
AT00988086T ATE269905T1 (en) | 1999-12-23 | 2000-12-14 | METHOD FOR PRODUCING PROTEINS IN HOST CELLS USING CHAPERONINS |
DK00988086T DK1208213T3 (en) | 1999-12-23 | 2000-12-14 | Process for producing proteins in host cells using chaperonins |
NZ517743A NZ517743A (en) | 1999-12-23 | 2000-12-14 | Production of toxic proteins in host cells by expressing as a fusion protein to chaperonin binding domains from GroES in the presence of a chaperonin GroEL |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/470,830 US6677139B1 (en) | 1999-12-23 | 1999-12-23 | Methods for production of proteins in host cells |
US09/470,830 | 1999-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001048227A1 true WO2001048227A1 (en) | 2001-07-05 |
WO2001048227A8 WO2001048227A8 (en) | 2001-10-04 |
Family
ID=23869226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/034055 WO2001048227A1 (en) | 1999-12-23 | 2000-12-14 | Method for production of proteins in host cells involving the use of chaperonins |
Country Status (9)
Country | Link |
---|---|
US (2) | US6677139B1 (en) |
EP (1) | EP1208213B1 (en) |
AT (1) | ATE269905T1 (en) |
AU (1) | AU2433401A (en) |
CA (1) | CA2385766C (en) |
DE (1) | DE60011785T2 (en) |
DK (1) | DK1208213T3 (en) |
NZ (1) | NZ517743A (en) |
WO (1) | WO2001048227A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114395576A (en) * | 2020-08-31 | 2022-04-26 | 南京工业大学 | Method for improving protein expression efficiency in clostridium |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0021757D0 (en) * | 2000-09-04 | 2000-10-18 | Colaco Camilo | Vaccine against microbial pathogens |
SI21273A (en) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Preparation of inclusion bodies with high fraction of properly twisted heterologous protein precursor |
DE10251547C5 (en) * | 2002-11-05 | 2008-05-21 | Biospring Gmbh | Recombinant (R) -hydroxynitrile lyase |
US20070037258A1 (en) * | 2005-08-09 | 2007-02-15 | The Board Of Trustees Operating Michigan State University | Methods and compositions for enhancing protein folding |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023042A1 (en) * | 1993-03-29 | 1994-10-13 | E.I. Du Pont De Nemours And Company | A method for enhancing the production of biologically active recombinant proteins |
WO1998056928A1 (en) * | 1997-06-13 | 1998-12-17 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Increased production of proteins by using chaperone-like proteins |
WO2000066756A1 (en) * | 1999-05-04 | 2000-11-09 | Timo Korpela | Microbial protein expression system |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3926103A1 (en) | 1989-08-08 | 1991-02-14 | Hoechst Ag | METHOD FOR THE BIOCATALYTIC CORRECT CHAIN FOLDING OF DENATURED RECOMBINANT FUSION PROTEINS |
ATE169671T1 (en) | 1990-09-13 | 1998-08-15 | Novo Nordisk As | LIPASE VARIANTS |
EP0681609A1 (en) | 1991-12-20 | 1995-11-15 | Novo Nordisk A/S | A process for the preparation of lipase |
WO1994008012A1 (en) | 1992-10-02 | 1994-04-14 | Research Corporation Technologies, Inc. | Methods for increasing secretion of overexpressed proteins |
IL109790A0 (en) | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US6068991A (en) | 1997-12-16 | 2000-05-30 | Bristol-Myers Squibb Company | High expression Escherichia coli expression vector |
-
1999
- 1999-12-23 US US09/470,830 patent/US6677139B1/en not_active Expired - Lifetime
-
2000
- 2000-12-14 CA CA002385766A patent/CA2385766C/en not_active Expired - Lifetime
- 2000-12-14 AT AT00988086T patent/ATE269905T1/en not_active IP Right Cessation
- 2000-12-14 WO PCT/US2000/034055 patent/WO2001048227A1/en active IP Right Grant
- 2000-12-14 AU AU24334/01A patent/AU2433401A/en not_active Abandoned
- 2000-12-14 NZ NZ517743A patent/NZ517743A/en not_active IP Right Cessation
- 2000-12-14 DE DE60011785T patent/DE60011785T2/en not_active Expired - Lifetime
- 2000-12-14 EP EP00988086A patent/EP1208213B1/en not_active Expired - Lifetime
- 2000-12-14 DK DK00988086T patent/DK1208213T3/en active
-
2003
- 2003-11-13 US US10/714,212 patent/US20040077038A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023042A1 (en) * | 1993-03-29 | 1994-10-13 | E.I. Du Pont De Nemours And Company | A method for enhancing the production of biologically active recombinant proteins |
WO1998056928A1 (en) * | 1997-06-13 | 1998-12-17 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Increased production of proteins by using chaperone-like proteins |
WO2000066756A1 (en) * | 1999-05-04 | 2000-11-09 | Timo Korpela | Microbial protein expression system |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114395576A (en) * | 2020-08-31 | 2022-04-26 | 南京工业大学 | Method for improving protein expression efficiency in clostridium |
CN114395576B (en) * | 2020-08-31 | 2023-11-14 | 南京工业大学 | Method for improving protein expression efficiency in clostridium |
Also Published As
Publication number | Publication date |
---|---|
DE60011785T2 (en) | 2005-07-14 |
EP1208213B1 (en) | 2004-06-23 |
DE60011785D1 (en) | 2004-07-29 |
CA2385766A1 (en) | 2001-07-05 |
NZ517743A (en) | 2003-07-25 |
US20040077038A1 (en) | 2004-04-22 |
AU2433401A (en) | 2001-07-09 |
EP1208213A1 (en) | 2002-05-29 |
CA2385766C (en) | 2009-07-14 |
WO2001048227A8 (en) | 2001-10-04 |
ATE269905T1 (en) | 2004-07-15 |
US6677139B1 (en) | 2004-01-13 |
DK1208213T3 (en) | 2004-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clos et al. | pJC20 and pJC40-two high-copy-number vectors for T7 RNA polymerase-dependent expression of recombinant genes in Escherichia coli | |
Khushoo et al. | Optimization of extracellular production of recombinant asparaginase in Escherichia coli in shake-flask and bioreactor | |
JPH09107954A (en) | Process for producing soluble protein by bacteria | |
US8008016B2 (en) | Vectors and methods for high throughput co-expressions | |
AU731049B2 (en) | Highly efficient controlled expression of exogenous genes in e. coli | |
JP5808671B2 (en) | No functional group II capsular gene cluster COLIBL21 strain | |
EP1208213B1 (en) | Method for production of proteins in host cells involving the use of chaperonins | |
US6660510B2 (en) | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom | |
JP4249832B2 (en) | Trigger factor expression plasmid | |
CA2467142C (en) | Improved method for the recombinant production of polypeptides | |
Mizobata et al. | Overproduction of Thermus sp. YS 8‐13 manganese catalase in Escherichia coli: Production of soluble apoenzyme and in vitro formation of active holoenzyme | |
JP3549210B2 (en) | Plasmid | |
de Vries et al. | Cloning and sequencing of the Proteus mirabilis gene for a single-stranded DNA-binding protein (SSB) and complementation of Escherichia coli ssb point and deletion mutations | |
EP0622460B1 (en) | Plasmid and escherichia coli transformed with it | |
US5384259A (en) | Construct and method for expression of tetracycline resistance genes in E. Coli | |
US20060141571A1 (en) | Method for promoting cell growth and increasing the production of the expressed target gene products | |
JP3709422B2 (en) | Regulators involved in nitrilase gene expression and genes thereof | |
EP2848691A1 (en) | Broad host range expression vector for diverse prokaryotes | |
JP2005034025A (en) | Plasmid vector for promoting expression of foreign gene in escherichia coli, recombinant escherichia coli, method for producing chemical substance with recombinant escherichia coli, and method for producing recombinant protein | |
WO2004016792A1 (en) | Novel expression vector suitable for expression of recombinant protein at low temperature | |
US20230407361A1 (en) | Inducible cell lysis system | |
US7820435B2 (en) | De novo synthesized plasmid, methods of making and use thereof | |
Reddy et al. | Fusing an insoluble protein to GroEL apical domain enhances soluble expression in Escherichia coli | |
CN113832127A (en) | Mutant of restriction enzyme BamH I and application thereof | |
Bose et al. | A Brief Introduction to Recombinant DNA Technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWE | Wipo information: entry into national phase |
Ref document number: 517743 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000988086 Country of ref document: EP Ref document number: 24334/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2385766 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000988086 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 517743 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 517743 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000988086 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |